The European Medicines Agency (EMA) announced on Wednesday that there was “a possible link between the AstraZeneca vaccine with cases of unusual blood clots with low blood platelets”. But these thromboses are “very rare” and observable “at all ages”.
“A plausible explanation for these rare side effects is an immune response to the vaccine, ”said Cooke, the executive director of the EMA, stressing that the vaccine is“ very effective ”and“ saves lives ”. The benefit / risk balance therefore remains positive for the vaccine from the British laboratory.
Several European countries have suspended the use of the vaccine from the Anglo-Swedish laboratory AstraZeneca due to reports of blood clots among those vaccinated. The European regulator had previously assured that the vaccine was not linked to a higher risk of blood clots, indicating, however, not being able to “definitively exclude” a link with rare coagulation disorders.
European Union health ministers are due to meet via video conference from 4 p.m. to discuss the EMA’s findings.
Support a professional editorial staff at the service of Brittany and the Bretons: subscribe from € 1 per month.